Market Place
Sourcing Support
Acadia Pharmaceuticals: Q1 2024 Financials, Operations
08 May 2024 //
BUSINESSWIRE
Acadia to stop trials of antipsychotic drug after it fails schizophrenia study
12 Mar 2024 //
REUTERS
MSN`s Generic Pimavanserin Receives Approval in the U.S.
16 Jan 2024 //
FDA
Delaware Federal District Court Rules in Favor of Acadia in NUPLAZID
13 Dec 2023 //
PRESS RELEASE
Acadia Pharmaceuticals Announces Label Update for NUPLAZID® (pimavanserin)
18 Sep 2023 //
PRESS RELEASE
Newly Published Analysis Showed Lower Mortality Risk Among PD`s with NUPLAZID
03 Jan 2023 //
BUSINESSWIRE
Aurobindo`s Generic Pimavanserin Receives Approval in the U.S.
07 Nov 2022 //
FDA
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
BUSINESS WIRE
Acadia hits another Nuplazid roadblock as the FDA doles out CRL
06 Aug 2022 //
ENDPTS
Why Acadia Pharmaceuticals Stock Is Crashing Today
21 Jun 2022 //
FOOL
MSN Lab`s Generic Pimavanserin Receives Tentative Approval in the U.S
03 Jun 2022 //
FDA
Acadia revives Nuplazid psychosis bid with Alzheimer`s focus
16 Feb 2022 //
FIERCEPHARMA
Sun Pharma gets SEC nod for phase III trial for antipsychotic drug pimavanserin
27 Jan 2022 //
PHARMABIZ
Cadila Healthcare`s US arm receives FDA nod to market Pimavanserin capsule
01 Jan 2022 //
ECONOMICTIMES
Zydus Cadila receives tentative approval from US FDA for Pimavanserin tablets
22 Dec 2021 //
EXPRESSPHARMA
Acadia is refiling Nuplazid in a narrower potential indication
22 Dec 2021 //
MARKETSCREENER
Acadia to resubmit its sNDA to U.S. FDA for NUPLAZID (pimavanserin)
20 Dec 2021 //
BUSINESSWIRE
The Lancet Psychiatry Publishes Results from Pimavanserin study in Schizophrenia
01 Dec 2021 //
BUSINESSWIRE
Evidence of sustained benefits of pimavanserin for dementia-related psychosis
22 Jul 2021 //
SCIENCEDAILY
NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE)
03 Jun 2021 //
BUSINESSWIRE
Acadia`s surprise FDA snag leaves Nuplazid expansion in limbo
11 Mar 2021 //
FIERCE PHARMA
ACADIA Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio
25 Aug 2020 //
BUSINESSWIRE
Pimavanserin Reduces Dementia-Related Psychosis Symptoms
03 Aug 2020 //
NEUROLOGYLIVE
Acadia’s shot at beating a ‘fickle’ major depression challenge misses the mark
21 Jul 2020 //
ENDPTS
ACADIA Announces USFDA Accepted for Filing the sNDA for NUPLAZID®
20 Jul 2020 //
PRESS RELEASE
ACADIA Pharmaceuticals Submits sNDA to U.S. FDA for NUPLAZID®
15 Jun 2020 //
PRESS RELEASE
ACADIA Pharma Submits Supplemental New Drug Application to U.S. FDA NUPLAZID®
15 Jun 2020 //
BUSINESSWIRE
ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Ph 3 Studies
26 May 2020 //
BUSINESSWIRE
ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020
21 May 2020 //
BUSINESSWIRE
Fresh off +ve Nuplazid data, Acadia adds new clinical drug from Vanderbilt
08 May 2020 //
ENDPTS
Acadia Receives Complete Response Letter from U.S. FDA for sNDA Pimavanserin
05 Apr 2020 //
BUSINESSWIRE
Acadia`s Nuplazid could hit blockbuster heights after strong psychosis data
05 Dec 2019 //
FIERCE PHARMA
Deciphera Announces Appointment of Ron Squarer to its Board of Directors
04 Dec 2019 //
BUSINESS WIRE
Acadia`s Nuplazid rebounds in schizophrenia with study win
27 Nov 2019 //
FIERCE PHARMA
ACADIA Pharmaceuticals Announces +Ve Top-line Results of Pimavanserin
25 Nov 2019 //
BUSINESS WIRE
ACADIA Pharmaceuticals Announces Positive Ph 2 CLARITY Results for Pimavanserin
24 Sep 2019 //
BUSINESSWIRE
Acadia calls early halt to Nuplazid psychosis trial
10 Sep 2019 //
FIERCE PHARMA
Acadia`s Nuplazid Fails to Prove Effectiveness in Schizophrenia Trial
23 Jul 2019 //
BIOSPACE
Acadia`s schizophrenia treatment misses late-stage main goal; shares fall 16%
22 Jul 2019 //
REUTERS
ACADIA`s to Present Ph2 CLARITY Results for Pimavanserin
20 May 2019 //
BUSINESSWIRE
Feds put Acadia`s Nuplazid marketing under the microscope
11 Mar 2019 //
FIERCE PHARMA
Acadia says Nuplazid cleared goal in depression study, but data appear mixed
31 Oct 2018 //
ENDPTS
FDA Reaffirming Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin)
22 Sep 2018 //
BUSINESSWIRE
ACADIA Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID
27 Apr 2018 //
BUSINESSWIRE
FDA strikes up review of Acadia`s Nuplazid
26 Apr 2018 //
FIERCE PHARMA
Acadia shares plunge on report FDA is re-examining its drug
26 Apr 2018 //
CNBC
ACADIA Pharma Initiates PhIII Study Pimavanserin in Dementia-Related Psychosis
09 Oct 2017 //
DDDMAG
Rumors Have Pfizer Eyeing This SoCal Biotech
06 Jan 2017 //
BIOSPACE
Acadia Pharmaceuticals Inc. (ACAD) Flirts With a Pfizer Inc. (PFE) Buyout
04 Jan 2017 //
NASDAQ
AKBA Inks Blockbuster Deal, AGN On Buying Spree, TSRO Gets FDA Date
21 Dec 2016 //
NASDAQ
Acadia Stock Screams Upward; Primary Endpoint Met in PhII Study
20 Dec 2016 //
BIOSPACE
The 21st Century Cures Act Will Not Fix The FDA
01 Dec 2016 //
FORBES
FDA`s internal review of Acadia`s Parkinson`s drug raise safety, benefit concern
28 Mar 2016 //
FIERCE BIOTECH
Acadia Pharma seeks US FDA approval for Nuplazid to treat Parkinson’s disease psychosis
04 Sep 2015 //
PHARMABIZ
